References
high-density lipoproteins-cholesterol, low-density lipoproteins, dyslipidemia
CML, TEM, DYSLIPIDEMIA
TEM image of VLDL (Comparison of the electromobility (TEM image of LDL (Comparison of the electromobility (Changes in the apoA-I contents in HDL, HDL-C, and %HDL-C in TC during 12 weeks of consumption of policosanol and placebo. HDL-C, high-density lipoproteins-cholesterol; TC, total cholesterol. (Comparison of the paraoxonase (PON-1) activity in HDLComparison of the ferric ion reduction ability (FRA) of HDLComparison of the protective activity of HDLProposed mechanism of policosanol to improve blood pressure and dyslipidemia after 12 weeks of consumption. apoA-I, apolipoprotein A-I; AST, aspartate transferase; ALT, alanine aminotransferase; CML, carboxymethyllysine; FRA, ferric ion reduction ability; γ-GTP, gamma-glutamyl transpeptidase; HbA1c, hemoglobin A1c; LDL, low-density lipoproteins; MDA, malondialdehyde; PON-1, paraoxonase-1; TC, total cholesterol; TG, triglyceride; VLDL, very low-density lipoproteins.Study design and participant allocation for analysis. Anthropometric profiles and blood parameters between the policosanol (20 mg) and placebo groups *.*, Data are expressed as the mean ± SEM (standard error of the mean). Repeated measures ANOVA of blood lipid parameters between the policosanol (PCO, 20 mg) and placebo groups *.*, Data are expressed as the mean ± SEM (standard error of the mean). Estimated statistical power is 92% based on the calculation using the program G*Power 3.1.9.7 (G*Power from University of Düsseldorf, Düsseldorf, Germany). Lipid compositions, oxidized extent, and extent of VLDL and LDL glycation between the policosanol and placebo groups.FI, fluorescence intensity (Ex = 370 nm, Em = 440 nm, 0.01 mg/mL of protein); MDA, malondialdehyde; TC, total cholesterol (μg/mg of protein); TG, triglyceride (μg/mg of protein); LDL, low-density lipoproteins; VLDL, very low-density lipoproteins. The data are expressed as the mean 